Deals
Horizon Buys Rare-Disease Company Raptor for $800 Million
- Deal will add Procysbi, Quinsair to Horizon portfolio
- Transaction expected to close in fourth quarter of 2016
This article is for subscribers only.
Horizon Pharma Plc agreed to buy Raptor Pharmaceutical Corp. for about $800 million to bolster its rare-disease treatment business and expand internationally.
Horizon will pay $9 a share in cash, about 21 percent more than Raptor’s closing price on Friday of $7.45, the companies said Monday in a statement. The transaction is expected to close in the fourth quarter of 2016, and should add to earnings next year, they said.